Comparative Effectiveness of Ivabradine Versus Digoxin in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease: A Real-World Multicenter Cohort Study.
Abstract
In this large, real-world cohort of patients with HFrEF and CKD, ivabradine was associated with lower risks of MACE, HFE, and all-cause mortality compared with digoxin. Ivabradine may represent a safer and more effective heart-rate-lowering option for this high-risk population.
What are the key findings of this study?
Ivabradine and digoxin are medications used to treat heart failure, which happens when the heart can't pump blood well. In a big study, ivabradine showed it helps people live longer and have fewer serious heart problems than digoxin, especially for those with kidney issues. This is important because finding safer treatments makes a big difference for patients. ❤️
Key Points
Objective
To compare the effectiveness of ivabradine versus digoxin in patients with heart failure and chronic kidney disease.
Methods
- Multicenter cohort study design
- Included patients with heart failure with reduced ejection fraction
- Compared outcomes between ivabradine and digoxin users
Results
- Ivabradine associated with lower risks of major adverse cardiac events
- Reduced heart failure events compared to digoxin
- Lower all-cause mortality in patients taking ivabradine
What is the clinical evidence from this study?
Study Design
Other
Key Finding
Ivabradine was associated with lower risks of MACE, HFE, and all-cause mortality compared with digoxin in patients with HFrEF and chronic kidney disease.